# A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

> **NCT02493712** · PHASE2 · COMPLETED · sponsor: **Holy Stone Healthcare Co., Ltd** · enrollment: 51 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** High dose
- **DRUG:** Low dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02493712
- **Lead sponsor:** Holy Stone Healthcare Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-07
- **Final completion:** 2019-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493712, "A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02493712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*